[Skip]

Steve Cubby's company Cannabis Science is getting ready to trade publicly. The U.S. company hopes to develop new medicines based on cannabis. Cubby is assigning his two patents to the company and CSI is hoping to secure government contracts for cannabis research. Cannabis Science is developing a cannabis lozenge to treat hypertension and cancer.

Here's the story:

As part of an effort to raise its profile, Cannabis Science, the San Francisco research and development firm aiming to develop cannabis-based medicines, has hired a Canadian company to provide it with investor relations services. In April, Cannabis got the OK from the U.S. Financial Industry Regulatory Authority to begin trading its shares over the counter under the symbol CBIS. Earlier this month the company touted the fact that it had received the necessary certification to work as a contractor for the U.S. government. It also named former Upjohn research scientist Mary Ruwart to head up its R&D efforts as it gears up to begin the drug development process with the Food and Drug Administration.
And two weeks ago the company said it was on the verge of filing two patents that have been assigned to the company by their inventor, Cannabis Science Chief Executive Steve Kubby.
Cannabis Science CEO, Steve Kubby, is the inventor who will assign both of his patents to Cannabis Science.

“Our new manufacturing process allows for the rapid and uniform harvesting of cannabis ‘trichomes,’ the part of the plant containing the active ingredient, THC. ” Kubby told potential investors. “Just as the cotton gin made cotton harvesting economically feasible, our innovative process will revolutionize trichome harvesting.”

Cannabis Science was formed earlier this year when Gulf Onshore, a Texas-based energy company that traded as a penny stock under the symbol GFON, agreed to acquire Cannex Therapeutics, a private San Francisco company involved in medical marijuana research in exchange for company stock.
The news lit a small fire under Cannabis shares, which rose Thursday one-and-a-half cents, or 9 percent, to close at a 18.5 cents.


Source:https://www.siliconbeat.com/2009/07/0...elations-firm/

[Tony Aroma]

Could be a great investment. And a steal. For $0.18 per share, you could get 1000 shares for only $180. If somewhere down the line they come up with a cure for cancer or some other miracle medicine, you'd be rich. If not, then you're not out that much. I'm seriously thinking about this one.

[oldschoolfarmer]

"CSI is hoping to secure government contracts for cannabis research" - good luck on that

[Expat]

While living in London I discovered and invested in GW Pharmaceuticals.
These folks have been at it since 1998. GW’s lead product, Sativex®, is approved and marketed in Canada for the relief of neuropathic pain in Multiple Sclerosis (MS)

[FreedomFGHTR]

DELETED BY AUTHOR

Interesting but be careful, there's a history of scams involving IPOs ( initial public offerings ). For instance someone could purchase their own stock to increase the price to show people a return, so they reinvest ( buy more shares ), then after they have sold enough shares crash the stock. Just saying do your research

[FreedomFGHTR]

DELETED BY AUTHOR

[DoobieDuck]

Originally Posted by Tony Aroma

Could be a great investment.

I'm thinking of how many great things can come of this. How great it is to hear that the company has overcome all the obsticals in getting started and is now ready to move forward with some serious research. Patients world wide may benifit from and the sooner the better. This is a major step forward.
thank you Skip for posting.. DD

True

[CANNACO-OP]

They stole my avatar? LOL, great link and article.

We always look at these opportunities as they are. Calculated risk. Spent $180 on worse investments.